Dabigatran (Pradaxa)

descriptionPublicationkeyboard_double_arrow_right Article 16 Feb 2012 English Publisher:American Society of Neuroradiology (ASNR)Journal:American Journal of Neuroradiology, volume 33, pages 426-428 (issn: 0195-6108, eissn: 1936-959X,

Copyright policy )

Authors: J, Comin; D F, Kallmes;

doi: 10.3174/ajnr.a3000

pmid: 22345499

pmc: PMC7966436

Dabigatran (Pradaxa)

- Summary
- Subjects
- Metrics

Abstract

Dabigatran (Pradaxa) is a member of the relatively new class of antithrombotic drugs known as direct thrombin inhibitors (DTIs). It may supplant warfarin (Coumadin) in a number of applications as it may produce a more predictable, potent, and immediate anticoagulant effect, with fewer significant side effects and interactions, and requires less monitoring.

Related Organizations

St Vincent's Hospital
Australia

Keywords

Dose-Response Relationship, Drug, beta-Alanine, Anticoagulants, Humans, Benzimidazoles, Hemorrhage, Thrombosis, Dabigatran

Impact byBIP!

	selected citations These citations are derived from selected sources. This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).	16
	popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.	Top 10%
	influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).	Average
	impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.	Average